Experience with Cutaneous Manifestations in COVID-19 Patients during the Pandemic.
COVID-19
cutaneous manifestations
dermatology
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Jan 2022
25 Jan 2022
Historique:
received:
25
12
2021
revised:
16
01
2022
accepted:
21
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
After the beginning of the SARS-CoV-2 pandemic, our dermatology department created a multidisciplinary unit to manage patients with cutaneous manifestations associated with COVID-19. With the objective of identifying skin lesions in patients with suspected COVID-19 and evaluating possible associations with systemic involvement, other infectious agents and coagulation disorders, we carried out a prospective observational study that included all patients that attended our COVID-19 dermatology clinic with a multidisciplinary protocol. A total of 63 patients (mean 34.6 years) were enrolled between May 2020 and February 2021. Overall, 27 patients (42.9%) had a positive COVID-19 test, and 74.6% had COVID-19 clinical signs. The most common skin lesion was maculopapular rash (36.5%), predominantly seen in male (54.2%) and older patients (42 vs. 30 years), followed by chilblain-like lesions (20.6%) in younger patients (13.9 vs. 20.9 years) who were predominantly barefoot at home (69.2%); these patients exhibited a tendency towards a negative COVID-19 test. A total of 12 patients (19.1%) had positive serology for herpesvirus 6 (IgM or IgG). We conclude that the COVID-19-associated skin lesions we observed were similar to those previously described. Questions as to the underlying mechanisms remain. Interferon, possibly aided by cold exposure, may cause perniosis-like lesions. Other cutaneous manifestations were similar to those caused by other viruses, suggesting that SARS-CoV-2 may reactivate or facilitate other viral infections.
Identifiants
pubmed: 35160051
pii: jcm11030600
doi: 10.3390/jcm11030600
pmc: PMC8836359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Dermatol. 2020 Jul;183(1):71-77
pubmed: 32348545
Br J Dermatol. 2021 Jul;185(1):214-216
pubmed: 33657646
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e291-e293
pubmed: 32330334
Dermatol Ther. 2020 Nov;33(6):e14170
pubmed: 32779280
Dermatol Ther. 2021 Jan;34(1):e14328
pubmed: 32986289
Dermatol Ther. 2020 Nov;33(6):e14096
pubmed: 32869938
Nutrients. 2020 Oct 31;12(11):
pubmed: 33142828
Br J Dermatol. 2022 Jan;186(1):142-152
pubmed: 34254291
J Med Virol. 2021 Apr;93(4):1850-1851
pubmed: 32970319
Eur J Dermatol. 2018 Dec 1;28(6):731-735
pubmed: 30530404
Actas Dermosifiliogr. 2022 Feb;113(2):T157-T165
pubmed: 34580541
Br J Dermatol. 2020 Dec;183(6):1145-1147
pubmed: 32790074
Dermatol Ther. 2020 Jul;33(4):e13730
pubmed: 32475003
Br J Dermatol. 2021 Jun;184(6):1187-1190
pubmed: 33420720
Dermatol Ther. 2021 Nov;34(6):e15153
pubmed: 34622531
Actas Dermosifiliogr (Engl Ed). 2021 Apr;112(4):314-323
pubmed: 33259815
JAMA Dermatol. 2021 Feb 1;157(2):202-206
pubmed: 33237291
Int J Dermatol. 2021 Jul;60(7):886-888
pubmed: 33686647
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e755-e757
pubmed: 32495368
J Am Acad Dermatol. 2020 Nov;83(5):1434-1436
pubmed: 32682889
Dermatol Ther (Heidelb). 2021 Aug;11(4):1119-1126
pubmed: 33999370
Skin Appendage Disord. 2021 Jul 08;21:1-5
pubmed: 34373830
Br J Dermatol. 2020 Nov;183(5):866-874
pubmed: 32628270
Cochrane Database Syst Rev. 2021 Aug 16;8:CD014963
pubmed: 34396514
JAMA Dermatol. 2022 Feb 1;158(2):217-218
pubmed: 34935876
Int J Infect Dis. 2021 Jan;102:53-55
pubmed: 33075530